The phrase peptide stack has migrated from bodybuilding forums into mainstream longevity podcasts over the past five years. By 2026 it is a recognizable genre: a named combination of injectable peptides, usually four to six compounds, presented as a "protocol" for recovery, longevity, cognitive function, or body composition. The aesthetic is scientific — dosages, cycling schedules, injection timing. The underlying evidence is almost always weaker than the aesthetic suggests. This article surveys what biohackers are actually stacking, who is promoting these protocols, and how the evidence holds up when you separate the randomized controlled trials from the anecdotes.
⚕️ General Disclaimer
This article describes peptide combinations that are circulating in the wellness and biohacker community in 2026. It is not an endorsement of any of these protocols. Most of the peptides discussed below are not FDA-approved, and several cannot be legally compounded for human use in the United States as of the 2023 FDA 503A action. Nothing here is medical advice. Do not self-administer unapproved peptides.
What Is a "Peptide Stack"?
In biohacker usage, a peptide stack is a prescribed combination of two or more peptides intended to produce a compound effect. The rationale is sometimes biological (synergistic mechanisms) and sometimes topical (different peptides for different goals combined into one regimen). Stacks are almost always defined by self-styled "protocols" — typically named after the person who popularized them — and shared through podcasts, newsletters, and paid community memberships.
Three things distinguish a peptide stack from an evidence-based combination therapy. First, the underlying peptides are usually individually unapproved. Second, the combination has essentially never been tested in a controlled trial. Third, the dosing and scheduling is derived from individual experience, vendor recommendations, or extrapolation from animal studies rather than from pharmacokinetic or pharmacodynamic data in humans.
None of this makes the stacks necessarily useless. It does make the confident protocol language they are wrapped in misleading.
Common Stacks in Circulation
The Recovery Stack: BPC-157 + TB-500
The most widely adopted combination in the "healing peptide" category. The rationale is that BPC-157 and TB-500 (or thymosin beta-4) target different aspects of tissue repair — BPC-157 through angiogenesis and cytoprotection, TB-500 through actin dynamics and cell migration — and together should accelerate recovery from tendon, ligament, or muscle injury more than either alone.
Evidence: Essentially none as a combination. BPC-157 has extensive preclinical literature concentrated in one research group and no published human RCTs. TB-500's human clinical data belongs to full-length thymosin beta-4 in narrow indications (corneal wound healing), not to the gray-market injectable product sold as TB-500. No combination trial exists. See our individual reviews of BPC-157 and TB-500.
Evidence grade: Anecdote + preclinical extrapolation. Not RCT-backed.
The Growth Hormone Stack: CJC-1295 + Ipamorelin
The canonical GH-axis stack. Rationale: GHRH analog (CJC-1295) combined with selective ghrelin receptor agonist (ipamorelin) should produce synergistic GH release that exceeds either peptide alone.
Evidence: Biological synergy between GHRH and ghrelin receptor pathways is real and established in animal studies and acute GH-release studies in humans. No RCT of the combination for any longevity, body composition, or functional outcome exists. The individual peptides' development programs both ended without reaching approval (CJC-1295 with DAC from ConjuChem, ipamorelin from Novo Nordisk for post-operative ileus). For context on how a properly developed GHRH analog gets to market, the comparator is tesamorelin, FDA-approved for HIV-associated lipodystrophy.
Evidence grade: Mechanistic plausibility + acute pharmacodynamic data + anecdote. No outcome trials.
The Longevity Stack: Epitalon + Thymalin (or Thymosin Alpha-1)
Russian-origin "longevity peptides" that have moved into the Western biohacker space. Epitalon is a tetrapeptide (Ala-Glu-Asp-Gly) developed in Soviet-era research by Vladimir Khavinson, claimed to extend telomeres and normalize circadian rhythms. Thymalin is a thymic peptide extract; thymosin alpha-1 (Zadaxin) is an actual approved drug in some countries for hepatitis B and as an immunomodulator.
Evidence: The Khavinson group has published multiple papers reporting lifespan extension and functional improvements with epitalon in animal studies and some small human cohorts. These studies have consistently drawn skepticism from Western reviewers regarding methodology, statistical power, and independent replication. Thymosin alpha-1 has real clinical data in specific immunomodulatory contexts; its use as a general longevity intervention is not supported by controlled trials. Injectable epitalon is sold almost exclusively through research-chemical channels.
Evidence grade: Single-group preclinical + limited small-cohort human data, not independently replicated.
The Brain Stack: GHK-Cu + Semax (and sometimes Selank, Cerebrolysin, or Dihexa)
Aimed at cognitive function, neuroprotection, and mood. GHK-Cu is a well-characterized tripeptide with extensive topical dermatology data; its systemic effects on gene expression have been characterized in cell culture (see our review of GHK-Cu and gene expression). Semax is a Russian-origin heptapeptide derived from ACTH, used in Russia as a stroke and cognitive treatment.
Evidence: GHK-Cu has legitimate cell biology literature on wound healing and gene expression modulation but essentially no controlled trials of systemic administration for cognitive outcomes. Semax has Russian clinical literature that is limited in Western peer-reviewed channels. Selank is in a similar position. Cerebrolysin (a porcine brain-derived peptide mixture) has the largest clinical footprint of the group, with trials in stroke and dementia, though results are mixed.
Evidence grade: Mixed — GHK-Cu has mechanistic cell data; semax/selank/cerebrolysin have limited Western clinical support.
The Body Composition Stack: Semaglutide or Tirzepatide + Tesamorelin (occasionally + BPC-157)
A newer combination that merges an approved GLP-1 agonist with an approved GHRH analog, on the premise that GLP-1 handles fat loss and tesamorelin preserves or increases lean mass while specifically targeting visceral fat. Both drugs are approved. Both are separately expensive. The combination has not been tested in controlled trials for general body composition.
Evidence grade: Individual drugs are well-evidenced in their specific indications; the combination is off-label improvisation.
The "Protocols From Podcasts" Phenomenon
A large share of specific dosing regimens and cycling schedules in circulation traces back to a handful of podcast episodes and newsletter posts. Ben Greenfield's extensive biohacking content includes detailed peptide protocols. Andrew Huberman's podcast has discussed peptides, generally with more caution than his critics acknowledge. Peter Attia's Drive podcast has interviewed peptide-prescribing physicians. Several anti-aging medicine clinics and their physician-owners have built sizable media presences around specific protocols.
The content quality varies enormously. Some episodes are careful about evidence grading and regulatory status. Others present dosing schedules as though they were derived from clinical trials when they were not. The pattern that recurs across the genre is that mechanistic plausibility is presented with the confidence usually reserved for outcome data. A listener can come away with the impression that "peptide X is clinically proven to do Y" when the evidence supports at most "peptide X binds receptor Z in cell culture, and one uncontrolled case series suggested that Y might improve."
This is not a problem unique to peptides. It is a general feature of the wellness-influencer information environment, and it applies to nootropics, supplements, and dietary interventions as much as it does to peptide stacks. But peptides are injected, sourced from the gray market, and regulated in a way that creates real legal and medical risk — so the stakes of confusing mechanism with evidence are higher here than in most other categories.
A Framework for Evidence Grading
Rather than recommending or rejecting specific stacks, a clearer approach is to organize peptides and peptide combinations by the tier of evidence that supports them. This framework is useful for anyone — patient, journalist, or physician — trying to read past the marketing language.
Tier 1: FDA-approved peptides with large RCT datasets. Semaglutide (obesity, diabetes), tirzepatide (obesity, diabetes), liraglutide, tesamorelin (HIV-associated lipodystrophy), pramlintide (diabetes), bremelanotide (hypoactive sexual desire disorder), oxytocin (labor), octreotide (acromegaly, carcinoid), leuprolide (prostate cancer, endometriosis), and several others. These have characterized efficacy, characterized safety, regulatory oversight, and clear labeled indications.
Tier 2: Peptides in active late-stage clinical development. Retatrutide, survodutide, amycretin, cagrilintide, orforglipron (non-peptide but relevant), and a handful of others in Phase 2/3 obesity and metabolic disease trials. These have emerging efficacy and safety data but are not yet approved.
Tier 3: Peptides with limited but real clinical data in specific indications. Thymosin alpha-1 (immunomodulation, approved in some countries), cerebrolysin (stroke, dementia, approved in some countries), thymosin beta-4 (topical corneal healing, in development). Evidence exists but is thinner or more narrowly indicated than Tier 1.
Tier 4: Research-chemical peptides with mechanistic or animal data but no controlled human trials for biohacker uses. BPC-157, TB-500, CJC-1295, ipamorelin, epitalon, thymalin, semax, selank, GHK-Cu (injected), dihexa, PT-141 (pre-approval formulations), melanotan II. This is where most of the stacks above live.
Tier 5: Peptides with essentially no meaningful evidence for the claims made about them. Various "designer" peptides marketed by research-chemical vendors with mechanism claims unsupported by published data.
No peptide stack built predominantly from Tier 4 and Tier 5 components can honestly be called evidence-based. It can be called biologically plausible, anecdotally reported, widely used — but not evidence-based. The framework protects against confusion between those categories.
Cost and Sourcing Problems
Tier 1 peptides are expensive because they are approved, insured (for labeled indications), and manufactured to GMP standards. Tier 4 peptides are cheap because they are manufactured in facilities of varying quality and sold as research chemicals with no regulatory oversight.
The cost comparison is therefore misleading in two directions. A biohacker paying $40 for a vial of CJC-1295 and $50 for a vial of ipamorelin may feel they are saving thousands compared to a tesamorelin prescription — but they are not purchasing the same quality-assurance standard or the same clinical confidence in what is in the vial. Meanwhile, a Tier 1 combination (semaglutide plus tesamorelin, for instance) can easily exceed $2,000/month at list price in the United States, which creates real pressure to substitute Tier 4 alternatives.
This cost asymmetry is one of the main structural forces driving the peptide-stack ecosystem. It is also the reason the FDA's 2023 503A action hit the peptide community so hard — it closed off the legal compounding pathway that had been a middle ground between GMP pharmaceutical pricing and unregulated research-chemical sourcing.
Connection to Gene Editing
The peptide-stack phenomenon matters to the gene-editing community for two reasons.
First, many of the pathways biohackers are targeting with peptide stacks are the same pathways that durable gene and cell therapies will eventually target — and the lessons learned (or not learned) from peptide use will shape patient expectations and physician comfort. The GLP-1/amylin/GIP axis is the most obvious example: today's injectable GLP-1 dosing is the behavioral precedent for tomorrow's single-dose gene therapy expressing the same effector. See how GLP-1 drugs work.
Second, the hierarchy-of-evidence framework above applies to the gene-editing field with equal force. A gene-therapy announcement based on mouse data and a press release is Tier 4 evidence; a therapy with Phase 3 data like Casgevy is Tier 1. The conceptual error of treating mechanism as outcome shows up in both communities, and the discipline required to resist it is the same. For the underlying biology of aging that both fields are trying to address, see hallmarks of aging.
Limitations
The biggest limitation of any peptide-stack review is that the field itself moves faster than the evidence. New stacks emerge every few months. Dosing schedules shift with each new podcast episode. The research-chemical marketplace is fluid. This article is a snapshot of what is circulating in early 2026, not a permanent taxonomy, and readers should expect specific protocols to drift in and out of fashion.
A second limitation is that "biohacker stacks" are heterogeneous. A Tier 1 physician-prescribed combination (semaglutide + tesamorelin for a specific patient) and a Tier 4 research-chemical stack (BPC-157 + TB-500 + CJC-1295 + ipamorelin + epitalon) share the label "peptide stack" but are not morally or medically equivalent. The framework above is meant to distinguish them; the label does not.
FAQ
Are any peptide stacks FDA-approved as combinations?
CagriSema (cagrilintide + semaglutide) is under regulatory review as a fixed-dose combination. No other "peptide stack" as currently marketed in biohacker channels is an approved combination.
Is it safer to get peptides from a compounding pharmacy?
Historically, yes — compounded products had pharmacist oversight and some quality assurance. The 2023 FDA 503A action removed many popular peptides from the compounding allowed list, so this pathway has narrowed considerably.
Why do podcasts promote these protocols if the evidence is weak?
Some hosts genuinely believe in the protocols based on personal experience and mechanistic reasoning. Some are commercially aligned with peptide clinics or supplement companies. Some are simply less rigorous about evidence grading than their audience assumes. The motives vary.
Can I trust a peptide clinic that prescribes these stacks?
Clinics vary enormously. Some are staffed by board-certified physicians practicing within the letter and spirit of off-label prescribing law. Others are cash-pay operations with weaker medical oversight. Ask what the peptide source is, whether it is compounded or research-chemical, and what the specific evidence base is for the protocol being recommended.
Which peptide has the strongest longevity evidence?
In the strict sense of randomized controlled trials with longevity or healthy-lifespan endpoints, none. The approved GLP-1 drugs have the strongest evidence for metabolic-disease outcomes, which map imperfectly onto "longevity." Everything else is extrapolation.
Is there a safer way to explore peptide therapy?
Yes — working with a physician, using FDA-approved peptides for their approved indications, and treating off-label use as the cautious, informed decision it should be. See our beginner's guide to peptides for longevity.
